Morgan Stanley initiated coverage of Pro Medicus (PMCUF) with an Overweight rating and A$300 price target PME Visage 7 software “creates significant value for its customers, underpinning our confidence on future contract opportunities,” says the analyst, who notes that the firm’s survey of 99 U.S. hospital executives found over 55% of respondents are likely to deploy Visage 7 over the next 12 months.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks